Lobbying firm

REGENXBIO

Gene Therapy Biotechnology Company

Filings
24
Clients
1
Total income
—
Lobbyists
1
Years active
2018–2023

Filings counts every document on the register, amendments included. Income is the fees reported to clients, counting the current version of each report once.

Income by year

Fees reported, $ thousands 2018 to 2023

Filings

24 filings, newest first.
Filing Client Income Expenses
4th Quarter - Termination
4th Quarter 2023
REGENXBIO — income $91,000 expenses
3rd Quarter - Report
3rd Quarter 2023
REGENXBIO — income $94,000 expenses
2nd Quarter - Report
2nd Quarter 2023
REGENXBIO — income $90,000 expenses
1st Quarter - Report
1st Quarter 2023
REGENXBIO — income $163,000 expenses
4th Quarter - Report
4th Quarter 2022
REGENXBIO — income $70,000 expenses
3rd Quarter - Report
3rd Quarter 2022
REGENXBIO — income $70,000 expenses
2nd Quarter - Report
2nd Quarter 2022
REGENXBIO — income $82,000 expenses
1st Quarter - Report
1st Quarter 2022
REGENXBIO — income $150,000 expenses
4th Quarter - Report
4th Quarter 2021
REGENXBIO — income $60,000 expenses
3rd Quarter - Amendment
3rd Quarter 2021
REGENXBIO — income $75,000 expenses

Clients

Everyone this filer has reported for, with the reports filed and the income they disclose.

ClientReportsIncome
REGENXBIO 22 —

Lobbyists

Everyone named on this filer's reports, with the government post they most recently disclosed here.

LobbyistCovered position, as disclosed
BRUCE ARTIM Senate Judiciary Committee Staff Member 1995-2006; (Chief Counsel and Staff Director 2003-04); Intellectual Property Subcommittee - Chief Counsel and Staff Director 2005-06)

From reports filed under the Lobbying Disclosure Act. A firm reports income from each client; an organisation lobbying for itself reports its own expenses instead. Each figure links to the filing it comes from.